AIM Immunotech Inc. - Q1 2026 10-Q Summary
Business Context and Reporting Period
Company: AIM Immunotech Inc.
Reporting Period: Quarter ended March 31, 2026
Business Overview: AIM is an immuno-pharma company developing Ampligen (rintatolimod) for late-stage pancreatic cancer and other indications. The company is currently focused on the DURIPANC Phase 2 clinical trial combining Ampligen with AstraZeneca's Imfinzi. Ampligen is approved in Argentina for Chronic Fatigue Syndrome (CFS) but not yet FDA-approved in the U.S.
Key Financial Metrics
| Metric ($ in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $22 | $16 |
| Net Loss | $(3,023) | $(3,705) |
| Operating Loss | $(2,226) | $(3,619) |
| Cash and Cash Equivalents (End of Period) | $5,816 | $898 |
| Total Current Assets | $6,214 | $3,295 |
| Total Current Liabilities | $6,145 | $6,224 |
| Working Capital | $69 | $(2,929) |
| Stockholders' Equity | $2,125 | $(3,857) |
| Debt (Current Portion, Net) | $4,004 | $3,549 |
Material Changes vs. Prior Period
- Net Loss Improvement: Net loss decreased by $682,000 (18.4%) compared to Q1 2025, driven primarily by a $1.4 million reduction in total costs and expenses.
- Expense Reductions:
- R&D: Decreased by $598,000 (55.4%) due to the abandonment of patents not aligned with the core pancreatic cancer focus and reduced clinical trial enrollment costs.
- G&A: Decreased by $783,000 (30.8%) primarily due to reduced legal fees following the settlement of a shareholder dispute.
- Warrant Liability Reclassification: A significant non-cash event occurred where Class E and F warrants were reclassified from liability to equity, increasing stockholders' equity by $8.7 million. This was triggered by a stock dividend that reset warrant terms.
- Liquidity Surge: Cash and cash equivalents increased by $2.8 million (94.8%) due to successful financing activities, including a Rights Offering ($1.8M), ATM sales ($2.0M), and warrant exercises ($2.2M).
- Interest Expense: Increased by $180,000 (145.2%) due to new debt obligations incurred in late 2025.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has disclosed substantial doubt about the company's ability to continue as a going concern for one year from the filing date. This is due to ongoing operating losses, limited working capital ($69k), and the need to raise additional capital to meet listing requirements.
- Delisting Risk: The company is currently non-compliant with NYSE American listing requirements regarding stockholders' equity (requires $6.0M; currently $2.1M). A compliance plan is in place with a deadline of June 11, 2026. Failure to comply may result in delisting.
- Clinical Outlook: The company is advancing the DURIPANC Phase 2 trial for pancreatic cancer. As of March 31, 2026, 24 patients have been treated. A Phase 3 trial design agreement was signed with Thermo Fisher Scientific in March 2026.
- Unusual Items:
- Recognized a $468,000 loss on the change in fair value of warrant liability prior to reclassification.
- Recognized a $32,000 loss on the issuance of warrants related to the Rights Offering.
- Subsequent Events: In May 2026, the company closed a warrant inducement transaction raising approximately $3.6 million and issued new Class H warrants.
Investor Verification Checklist
- Capital Raise Execution: Verify if the company successfully raises the additional ~$4 million needed to meet the $6 million NYSE equity requirement by June 11, 2026.
- Debt Maturity: Confirm the repayment status of the Streeterville Capital notes, with a significant portion ($4.0M) due within the next 12 months (maturity extended to June 30, 2026 for one note).
- Clinical Trial Progress: Monitor enrollment and interim data release for the DURIPANC Phase 2 pancreatic cancer trial, which is critical for future valuation and partnership opportunities.
- Warrant Inducement Impact: Assess the dilution impact of the May 2026 warrant inducement transaction (7.45M shares exercised, 14.9M new warrants issued).
- Argentina Operations: Evaluate the commercial viability of Ampligen in Argentina given the country's hyper-inflation and the shift in focus from CFS to pancreatic cancer.